Resveratrol-Curcumin Nanoparticle Composition for Obstructive Sleep Apnea
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obstructive sleep apnea (OSA) are expensive, invasive, and have low patient compliance, necessitating the development of effective, low-cost, and convenient therapeutic options.
Innovation Solution
A pharmaceutical composition comprising resveratrol and/or curcumin compounds, combined with pharmaceutically acceptable carriers and non-ionic surfactants, formulated as nanoparticles to alleviate OSA symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CPAP or OAT devices are used to treat OSA, then the airway can be kept open and unobstructed, but the treatment cost increases and patient compliance decreases
Solution Approach 1:
The patent replaces mechanical treatment systems (CPAP machines, oral appliances) with a pharmacological approach using small molecule compounds that directly relax upper airway muscles. This substitution eliminates the need for bulky devices and complex machinery, thereby improving patient compliance while maintaining airway patency through biochemical mechanisms.
Solution Approach 2:
The patent introduces small molecule compounds as biochemical intermediaries that mediate the relaxation of upper airway muscles. These compounds act as mediators between the therapeutic goal (open airway) and the physiological mechanism (muscle relaxation), providing a more convenient alternative to mechanical devices while achieving the desired airway patency.
2Reliability
If CPAP or OAT devices are used to treat OSA, then the airway can be kept open and unobstructed, but the treatment cost increases
Solution Approach 1:
The patent employs small molecule compounds that can be administered systemically and eliminated naturally by the body, replacing expensive, reusable mechanical devices. This approach uses inexpensive pharmacological agents that achieve the therapeutic effect temporarily but can be readministered, significantly reducing overall treatment costs while maintaining airway patency.
Solution Approach 2:
The patent replaces expensive mechanical treatment systems with affordable pharmacological compounds. By substituting machinery and devices with small molecule drugs, the treatment becomes more cost-effective while maintaining the reliability of airway opening through biochemical rather than mechanical means.
3Reliability
If surgical procedures are performed to treat OSA, then the airway obstruction can be relieved, but side effects occur and success rates vary
Solution Approach 1:
The patent replaces invasive surgical mechanical interventions with non-invasive pharmacological treatment. Small molecule compounds are administered systemically to achieve muscle relaxation and airway opening without physical cutting, tissue removal, or structural modification, thereby eliminating surgical side effects while maintaining airway obstruction relief.
Solution Approach 2:
The patent introduces small molecule compounds as biochemical intermediaries that mediate airway opening through muscle relaxation. This intermediary approach avoids direct mechanical or surgical intervention on the airway structures, preventing the harmful side effects associated with surgery while still achieving relief from airway obstruction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces OSA symptoms such as snoring and breathing pauses, offering a convenient and potentially more compliant treatment alternative to existing methods.
Implementation Method 1
the first pharmaceutically acceptable non-ionic surfactant forms a first plurality of micelles with the resveratrol compound and/or the curcumin compound
Data Source
AI summary
A method for alleviating a symptom associated with obstructive sleep apnea (OSA), the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition, which comprises: (a) a resveratrol compound and/or a curcumin compound; and (b) a pharmaceutically acceptable carrier.